My long-term research interest is centered around leveraging fundamental knowledge about cancer to develop the next generation of immunotherapeutics with improved efficacy across cancer subtypes and reduced off-target effects. By creating technologies to study aspects of fundamental cancer biology and how immunotherapies are affected by different cellular and secreted factors, researchers will be informed of the parameters critical to a given therapy’s success. Developing robust in vitro models such as the TLI-Ivatar that can effectively maintain critical immune populations and predict human disease outcomes will advance immunotherapeutic design.